Pfizer to settle over 10K lawsuits linking Zantac to cancer

Pfizer has agreed to settle over 10,000 lawsuits alleging that Zantac, an anti-heartburn medication, posed cancer risks that were not disclosed to patients. Despite these settlements, Pfizer still faces significant legal exposure. Zantac, introduced in 1983 and once the world's best-selling drug, was removed from the market in 2020 after being found to contain the carcinogen NDMA. This settlement follows a similar agreement by Sanofi, resolving most of its U.S. lawsuits, excluding those in Delaware where major cases are still pending.